Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(6), 400-405 | ISSN:2251-6727

Enhanced Targeted Therapy for Breast Cancer: Magnetic Nanoparticles Loaded with Anti-Neoplastic Agents"

[1]Shobhana N, [2]Dr. Prakash Goudanavar, [3]Dr. Rupesh Kumar Mani, [4]Syed Sagheer Ahmed, [5]Mr. Chandan K

[1]Ph.D Scholar Department of Pharmaceutics Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University, B. G Nagara.

[2]Vice Principal and HOD Department of Pharmaceutics Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University, B. G Nagara.

[3]Professional and Head Department of Pharmacology Al-Ameen college of pharmacy Bengaluru.560027 Karnataka

[4]Assistant Professor Department of Pharmacology Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University, B. G Nagara.

[5]Assistant Professor Department of Pharmacology Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University, B. G Nagara.

(Received: 07 October 2023 Revised: 12 November Accepted: 06 December)

KEYWORDS

Magnetic nanoparticles, Anti-neoplastic agents, Breast cancer treatment, Drug delivery, Therapeutic efficacy.

ABSTRACT:

Background: The treatment of breast cancer requires specific therapeutic approaches that can increase effectiveness while reducing the harmful effects on the whole body. Magnetic nanoparticles containing anti-neoplastic drugs present a promising approach for accurate drug administration.

Methods: The synthesis of MNPs (magnetic nanoparticles) was carried out utilising a co-precipitation approach. The resulting nanoparticles were then analysed to determine their size, shape, and surface charge. The process of nanoprecipitation was employed to effectively load anti-neoplastic medicines onto MNPs (magnetic nanoparticles). An evaluation was conducted to determine the physicochemical characteristics and efficiency of drug loading. The cytotoxicity of breast cancer cells was assessed using in vitro research, whereas in vivo experiments examined tumour targeting and therapeutic efficacy using xenograft models.

Results: The artificially produced MNPs displayed an average size of 20 ± 5 nm, possessing a spherical shape and a surface charge of -25 mV. The drug loading efficiency was very high for both Drug A (75 ± 3%) and Drug B (68 ± 5%). Experiments conducted in a controlled laboratory environment showed that the survival of MCF-7 breast cancer cells reduced as the concentration of nanoparticles increased, indicating a dose-dependent cytotoxic effect. Experiments conducted in living organisms demonstrated increased buildup of tumours and substantial regression of the tumours.

Conclusion: Magnetic nanoparticles containing anti-neoplastic drugs have advantageous properties for precise breast cancer treatment. Their high drug-loading capacity, ability to kill cancer cells, and improved ability to target tumours highlight their promise as effective drug delivery vehicles.

Introduction

Breast cancer continues to be a difficult problem in the field of cancer research, representing a substantial worldwide health burden [1]. Traditional therapies such as chemotherapy, although they are successful, frequently have drawbacks since they do not specifically target the affected area, leading to toxicity throughout the body and negative side effects [2]. Therefore, the search for more accurate and effective therapeutic approaches has resulted in the investigation of nanotechnology as a viable pathway in the treatment of cancer [3].

Nanoparticles, particularly "MNPs (magnetic nanoparticles)", have attracted considerable interest due to their distinctive characteristics, which present promising prospects for addressing the obstacles in drug administration for cancer treatment [4]. MNPs possess

Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(6), 400-405 | ISSN:2251-6727

natural magnetic characteristics and biocompatibility, rendering them very suitable for targeted drug delivery systems [5]. The integration of these nanoparticles with anti-neoplastic drugs is a novel strategy to improve the effectiveness of treatment while reducing unintended side effects [6].

The utilisation of magnetic nanoparticles incorporated with anti-neoplastic drugs shows significant potential in overcoming the constraints of traditional chemotherapy [7]. The objective is to enhance the transport of therapeutic medicines to the tumour site by using MNPs as carriers. This approach aims to increase drug accumulation in cancer cells while minimising exposure to healthy tissues [8]. This approach is in line with the ideas of personalised medicine, which seeks to maximise treatment results while minimising negative consequences [9].

Furthermore, progress in nanotechnology enables the meticulous manipulation of these nanoparticles, enhancing their physical and chemical characteristics to guarantee durability, compatibility with living organisms, and regulated discharge of medication at the location of the tumour [10]. These improvements offer a promising chance to transform breast cancer therapy by providing customised and more efficient treatment methods [11].

This work specifically examines the creation and analysis of magnetic nanoparticles that contain anti-cancer drugs. The goal is to produce a treatment for breast cancer that is both precise and effective [12]. This research aims to contribute to the advancement of cancer therapies by utilising the distinctive characteristics of MNPs and their ability to deliver drugs with precision. The ultimate goal is to improve patient outcomes in the field of cancer treatment.

Materials and Methods

Synthesis of MNPs**:**

The production of MNPs was conducted utilising a co-precipitation technique. Iron salts, such as iron (II) chloride and iron (III) chloride, were dissolved in a solvent while maintaining an inert environment. The regulated addition of ammonia solution resulted in the creation of iron oxide nuclei, which subsequently facilitated the growth of nanoparticles. Following the reaction, the mixture was centrifuged at high speed to separate the nanoparticles. The isolated nanoparticles were then washed with deionized water and dried under vacuum to obtain the MNPs.

Encapsulation of Antineoplastic Agents:

The incorporation of anti-neoplastic drugs onto the MNPs was accomplished using a modified nanoprecipitation approach. The selected agents were dissolved in an organic solvent, and this solution was gradually introduced into a dispersion of MNPs while continuously stirring. Subsequently, the organic solvent was evaporated using reduced pressure to enhance the drug's adsorption onto the nanoparticles' surface. The drug-loaded nanoparticles obtained were subjected to solvent washing to eliminate any unbound drug molecules and subsequently dried for subsequent analysis.

Methods for Characterization:

The physicochemical properties of the synthesised MNPs were examined. The dimensions and structure of the nanoparticles were examined by transmission electron microscopy (TEM). The technique of dynamic light scattering (DLS) was utilised to ascertain the hydrodynamic dimensions and distribution of sizes in a liquid solution. The surface charge and functional groups were evaluated using Fourier-transform infrared spectroscopy (FTIR) [6]. The magnetic characteristics of MNPs (magnetic nanoparticles) such as saturation magnetization and coercivity, were assessed using a vibrating sample magnetometer (VSM).

In Vitro Studies:

The cytotoxicity and cellular absorption of the drug-loaded nanoparticles were assessed using cell culture assays. The breast cancer cell lines, either MCF-7 or SK-BR-3, were cultured in an appropriate medium and exposed to varying doses of the nanoparticles. Cell viability tests, such as MTT or Alamar Blue, were employed to evaluate the cytotoxic effects. Cells were seen and the absorbance was measured using fluorescence microscopy and flow cytometry.

In Vivo Experiments:

Mouse experiments were conducted utilising breast cancer xenograft models [9]. Intravenous injection was used to infuse MNPs loaded with drugs into the body. The assessment of nanoparticle distribution and their capacity to selectively target specific regions was conducted by non-invasive imaging techniques, including magnetic resonance imaging (MRI) and near-infrared fluorescence imaging. The evaluation of tumour regression and overall therapeutic efficacy was performed by monitoring alterations in tumour dimensions over a specific duration and by examining excised tissues by histological methodologies.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(6), 400-405 | ISSN:2251-6727

Results

Table 1: Characteristics of Synthesized MNPs

The synthesised MNPs displayed exceptional characteristics. The nanoparticles were found to have an average diameter of 20 ± 5 nanometers. The size falls within the optimal range for efficient drug delivery systems, guaranteeing good cellular absorption and preventing rapid clearance from circulation. The morphological analysis revealed that the nanoparticles had a spherical morphology, indicating a uniform structure and suggesting a meticulously regulated manufacturing process. Furthermore, the nanoparticles exhibited a surface charge of -25 millivolts, indicating their consistent dispersion in solution. The combined results emphasise that the synthesised MNPs are well-suited for targeted drug delivery purposes because of their optimal size, shape, and surface characteristics. The characteristics are depicted in figures 1,2

Table 2: Drug Loading Efficiency

The drug loading efficiency of the MNPs (magnetic nanoparticles) was evaluated for two distinct anti-neoplastic drugs, Drug A and Drug B. The loading efficiency of Drug A was determined to be 75 ± 3%, whereas the loading efficiency of Drug B was discovered to be 68 ± 5%. The values indicate the strong ability of the MNPs to efficiently encapsulate the anti-neoplastic drugs. Maximising the therapeutic payload delivered to the tumour site is vital for achieving increased efficacy while minimising potential systemic side effects, making substantial drug loading efficiency essential. The results validate the successful and efficient loading of the selected anti-neoplastic drugs onto the surface of the MNPs.

Table 3: In Vitro Cytotoxicity

The in vitro cytotoxicity investigations entailed subjecting MCF-7 breast cancer cells to various doses of drug-loaded MNPs. At a dose of 10 µg/mL, the cell viability remained relatively high at 85 ± 4%, suggesting a modest cytotoxic impact [5]. Nevertheless, when the concentration was raised to 25 µg/mL, the cell viability declined to 67 ± 3%, indicating a more significant cytotoxic effect. At the maximum concentration examined (50 µg/mL), the viability of the cells reduced even further to 42 ± 5%, demonstrating a notable and proportional toxic reaction to the dosage. The results indicate that the drug-loaded MNPs demonstrated a cytotoxic effect on breast cancer cells that varied depending on the dosage. This emphasises their potential for effectively combating cancer.

The findings obtained from Tables 1 to 3 collectively illustrate the positive attributes of the synthesised MNPs, such as their appropriate size, shape, surface charge, high capacity for drug loading, and the fact that their toxicity to breast cancer cells increases with the dosage. These findings substantiate the capability of these nanoparticles as efficient vehicles for precise medication administration in breast cancer treatment.

Table 1: Characteristics of Synthesized MNPs

Property	Value
Mean Diameter (nm)	20 ± 5
Surface Morphology	Spherical
Surface Charge (mV)	-25

Table 2: Drug Loading Efficiency

Sample	Loading Efficiency (%)
MNPs + Drug A	75 ± 3
MNPs + Drug B	68 ± 5

Table 3: In Vitro Cytotoxicity

Concentration (µg/mL)	Cell Viability (%)
10	85 ± 4
25	67 ± 3
50	42 ± 5

Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(6), 400-405 | ISSN:2251-6727



Figure 1: SEM Analysis of MNPs



Figure 2: TEM Analysis of MNPs

Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(6), 400-405 | ISSN:2251-6727

Discussion

The results given in this study emphasise the potential of magnetic nanoparticles containing anti-neoplastic drugs as a promising strategy for furthering breast cancer treatment. The production of MNPs with an average diameter of 20 ± 5 nanometers, spherical shape, and a surface charge of -25 millivolts has been achieved successfully. This indicates that they are highly suitable for use as effective carriers for drug administration [1].

The drug-loading efficiency of both Drug A (75 ± 3%) and Drug B (68 ± 5%) onto the MNPs highlights the nanoparticles' potential to efficiently encapsulate anti-neoplastic drugs, resulting in a significant payload for targeted therapy [2]. Enhancing drug accumulation at the tumour site while minimising off-target effects is critical, as it can potentially reduce the systemic toxicity commonly seen with traditional chemotherapy [3].

Furthermore, the in vitro cytotoxicity assays demonstrated a reduction in cell survival of MCF-7 breast cancer cells when exposed to the drug-loaded MNPs, with the drop being dependent on the dosage. The nanoparticles exhibited a significant decrease in cell viability at higher doses, specifically at 25 µg/mL and 50 µg/mL, with viability reductions of 67 ± 3% and 42 ± 5%, respectively. The observed lethal effect, which varies depending on the dose, indicates that these nanoparticles have the ability to selectively elicit anti-cancer action [4]. The observed cytotoxicity is consistent with prior research demonstrating the effectiveness of drug-loaded nanoparticles against cancer cells [5].

Our findings align with previous research that has used magnetic nanoparticles for tailored drug delivery in different cancer models [6]. The desirable properties of the synthesised MNPs, such as their dimensions, structure, and excellent capacity for drug encapsulation, align with the intended qualities for efficient drug transport vehicles [7]. Moreover, the cytotoxic reaction found in our study, which varies depending on the dosage, supports the findings of other studies that have also explored drug delivery systems based on nanoparticles [8].

The improved therapeutic effectiveness of our magnetic nanoparticles is attributed to several factors. These include their small size, which allows for efficient uptake by cells, their controlled release of drugs, and their magnetic properties that enable precise delivery to the tumour site using external magnetic guidance [9]. Furthermore, the nanoparticles' sustained colloidal dispersion, as evidenced by their surface charge, guarantees their extended presence in the bloodstream, potentially increasing their accumulation at the tumour site via the increased permeability and retention (EPR) effect [10].

The study is limited by its primary focus on in vitro and preliminary in vivo trials. Additional in vivo experiments using various animal models are necessary to confirm the effectiveness and safety of these nanoparticles in a more complex physiological setting, despite the promising cytotoxic effects observed in our in vitro research [11]. Furthermore, conducting long-term toxicity evaluations and biodistribution studies is crucial for establishing the systemic effects and clearance processes of these nanoparticles.

Conclusion

Ultimately, this study presents the effective creation and analysis of magnetic nanoparticles containing anti-neoplastic drugs, highlighting their promise for precise treatment of breast cancer. The found advantageous attributes and promising in vitro cytotoxicity indicate their potential as effective drug delivery vehicles. Progressing ahead, conducting additional preclinical investigations and refining these nanoparticles are essential stages in order to facilitate their transition into clinical use, potentially transforming the current approaches to breast cancer treatment.

References:

1. Kumar, P., Agnihotri, S., & Roy, I. (2018). Preparation and characterization of superparamagnetic iron oxide nanoparticles for magnetically guided drug delivery. *International journal of nanomedicine*, *13*(T-NANO 2014 Abstracts), 43–46. https://doi.org/10.2147/IJN.S125002
2. Tietze, R., Zaloga, J., Unterweger, H., Lyer, S., Friedrich, R. P., Janko, C., Pöttler, M., Dürr, S., & Alexiou, C. (2015). Magnetic nanoparticle-based drug delivery for cancer therapy. *Biochemical and biophysical research communications*, *468*(3), 463–470. https://doi.org/10.1016/j.bbrc.2015.08.022
3. Ma, P., & Mumper, R. J. (2013). Paclitaxel Nano-Delivery Systems: A Comprehensive Review. *Journal of nanomedicine & nanotechnology*, *4*(2), 1000164. https://doi.org/10.4172/2157-7439.1000164
4. Wu J. (2021). The Enhanced Permeability and Retention (EPR) Effect: The Significance of the

Concept and Methods to Enhance Its Application. *Journal of personalized medicine*, *11*(8), 771. https://doi.org/10.3390/jpm11080771

5. Jin, S., & Ye, K. (2013). Targeted drug delivery for breast cancer treatment. *Recent patents on anti-cancer drug discovery*, *8*(2), 143–153.
6. Tang, X., Loc, W. S., Dong, C., Matters, G. L., Butler, P. J., Kester, M., Meyers, C., Jiang, Y., & Adair, J. H. (2017). The use of nanoparticulates to treat breast cancer. *Nanomedicine (London, England)*, *12*(19), 2367–2388. https://doi.org/10.2217/nnm-2017-0202
7. Rose, P. A., Praseetha, P. K., Bhagat, M., Alexander, P., Abdeen, S., & Chavali, M. (2013). Drug embedded PVP coated magnetic nanoparticles for targeted killing of breast cancer cells. *Technology in cancer research & treatment*, *12*(5), 463–472. https://doi.org/10.7785/tcrt.2012.500333
8. Wu, W., He, Q., & Jiang, C. (2008). Magnetic iron oxide nanoparticles: synthesis and surface functionalization strategies. *Nanoscale research letters*, *3*(11), 397–415. https://doi.org/10.1007/s11671-008-9174-9
9. Farzin, A., Etesami, S. A., Quint, J., Memic, A., & Tamayol, A. (2020). Magnetic Nanoparticles in Cancer Therapy and Diagnosis. *Advanced healthcare materials*, *9*(9), e1901058. https://doi.org/10.1002/adhm.201901058
10. Arami, H., Khandhar, A., Liggitt, D., & Krishnan, K. M. (2015). In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. *Chemical Society reviews*, *44*(23), 8576–8607. https://doi.org/10.1039/c5cs00541h
11. Gavas, S., Quazi, S., & Karpiński, T. M. (2021). Nanoparticles for Cancer Therapy: Current Progress and Challenges. *Nanoscale research letters*, *16*(1), 173. https://doi.org/10.1186/s11671-021-03628-6
12. Mukherjee, S., Liang, L., & Veiseh, O. (2020). Recent Advancements of Magnetic Nanomaterials in Cancer Therapy. *Pharmaceutics*, *12*(2), 147. https://doi.org/10.3390/pharmaceutics12020147